Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Naoto Takahashi Chiaki Nakaseko |
| Publication date | April 30, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |